Zimmer Biomet (ZBH) Set to Announce Earnings on Wednesday

Zimmer Biomet (NYSE:ZBH) is anticipated to release its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of $1.88 per share and revenue of $2.04 billion for the quarter. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $2.01 by $0.06. The firm had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. The business’s revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the firm earned $2.07 EPS. On average, analysts expect Zimmer Biomet to post $8.54 EPS for the current fiscal year and $8.98 EPS for the next fiscal year.

Zimmer Biomet Trading Up 0.6%

Zimmer Biomet stock opened at $96.66 on Wednesday. Zimmer Biomet has a one year low of $79.12 and a one year high of $103.70. The stock has a fifty day moving average of $95.08 and a 200 day moving average of $91.65.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Wednesday, September 30th.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, insider Kevin R. Thornal sold 5,691 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Chad Phipps sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the sale, the insider directly owned 65,231 shares in the company, valued at approximately $6,415,468.85. This represents a 4.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.28% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ZBH. Weiss Ratings raised shares of Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. UBS Group reiterated a “buy” rating and issued a $120.00 price objective on shares of Zimmer Biomet in a research note on Thursday, August 6th. Citigroup reissued a “neutral” rating on shares of Zimmer Biomet in a report on Monday, October 5th. Robert W. Baird set a $104.00 target price on shares of Zimmer Biomet in a research report on Thursday, August 6th. Finally, Stifel Nicolaus upped their target price on shares of Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Seven investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and an average target price of $104.47.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.